Roberts Capital Advisors LLC Buys Shares of 6,321 Merck & Co., Inc. $MRK

Roberts Capital Advisors LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 6,321 shares of the company’s stock, valued at approximately $531,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares during the last quarter. National Pension Service boosted its position in shares of Merck & Co., Inc. by 4.9% during the 2nd quarter. National Pension Service now owns 5,531,803 shares of the company’s stock worth $437,898,000 after purchasing an additional 258,320 shares during the period. SBI Securities Co. Ltd. increased its holdings in Merck & Co., Inc. by 11.6% in the 2nd quarter. SBI Securities Co. Ltd. now owns 24,436 shares of the company’s stock valued at $1,934,000 after purchasing an additional 2,535 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp raised its position in Merck & Co., Inc. by 3.3% in the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 2,308,513 shares of the company’s stock valued at $182,742,000 after purchasing an additional 74,494 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Down 0.7%

MRK stock opened at $116.21 on Thursday. The company’s 50 day moving average price is $114.86 and its 200 day moving average price is $99.26. The firm has a market capitalization of $287.32 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 2.27 and a beta of 0.27. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research reports. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. UBS Group lifted their target price on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company increased their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Zacks Research cut shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $125.88.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive late?stage clinical results across oncology and HIV programs — Phase 3 data for KEYTRUDA and WELIREG showed improved survival/expanded indications in kidney, ovarian and bladder cancer, and Merck highlighted progress on its DOR/ISL HIV program; these outcomes support revenue growth potential from high?margin specialty drugs. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Recent earnings and guidance remain supportive — Merck posted an EPS beat and set FY2026 guidance, which underpins expectations for profitability and cash generation that fund R&D, buybacks, and dividends. (Earnings referenced from Merck’s Feb results.)
• Neutral Sentiment: Broader market reports note expanding markets for several of Merck’s products (neuroendocrine carcinoma, vaccines like Ervebo, M?M?R II, and fertility drug Elonva); these reports signal longer?term TAM expansion but are not near?term catalysts by themselves. Neuroendocrine Carcinoma Market Poised for Significant Growth Ervebo (Merck & Co) Market Research Report 2026 M-M-R II (Merck & Co) Market Research Report 2026 Elonva (Merck & Co) Market Research Report 2026
• Neutral Sentiment: Short?term price momentum: recent coverage noted MRK moving higher within the S&P 500 and outperforming the market on some sessions — useful context for market positioning but not a fundamental change. Merck & Co. Moves Higher Within S&P 500 Index Amid Gains Merck (MRK) Rises Higher Than Market: Key Facts
• Negative Sentiment: Analyst caution on Winrevair — RBC flagged that Winrevair needs to show at least a 20?meter improvement on the 6?minute walk test to build confidence; failure to meet clinically meaningful thresholds could weigh on sentiment for that respiratory program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.